MABPHARM-B (02181) released its interim results for 2025, reporting operating revenue of RMB 274 million, representing a year-over-year increase of 152.7%. The company recorded shareholders' attributable profit of RMB 2.898 million, compared to a shareholders' attributable loss of RMB 97.569 million in the same period last year, successfully turning from loss to profit year-over-year. Basic earnings per share stood at RMB 0.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.